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Abstract
Background: Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes,
resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival.
Whilst Sorafenib and Lenvatinib are now licenced for the treatment of progressive iodine refractory thyroid cancer,
these treatments require continuing treatment and can be associated with significant toxicity.
Evidence from a pilot study has demonstrated feasibility of Selumetinib to allow the reintroduction of I-131 therapy;
this larger, multicentre study is required to demonstrate the broader clinical impact of this approach before
progression to a confirmatory trial.
Methods: SEL-I-METRY is a UK, single-arm, multi-centre, two-stage phase II trial. Participants with locally advanced
or metastatic differentiated thyroid cancer with at least one measureable lesion and iodine refractory disease will be
recruited from eight NHS Hospitals and treated with four-weeks of oral Selumetinib and assessed for sufficient I-123
uptake (defined as any uptake in a lesion with no previous uptake or 30% or greater increase in uptake). Those with
sufficient uptake will be treated with I-131 and followed for clinical outcomes. Radiation absorbed doses will be
predicted from I-123 SPECT/CT and verified from scans following the therapy. Sixty patients will be recruited to
assess the primary objective of whether the treatment schedule leads to increased progression-free survival
compared to historical control data.
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Discussion: The SEL-I-METRY trial will investigate the effect of Selumetinib followed by I-131 therapy on
progression-free survival in radioiodine refractory patients with differentiated thyroid cancer showing increased
radioiodine uptake following initial treatment with Selumetinib. In addition, information on toxicity and dosimetry
will be collected. This study presents an unprecedented opportunity to investigate the role of lesional dosimetry in
molecular radiotherapy, leading to greater personalisation of therapy. To date this has been a neglected area of
research. The findings of this trial will be useful to healthcare professionals and patients alike to determine whether
further study of this agent is warranted. It is hoped that the development of the infrastructure to deliver a
multicentre trial involving molecular radiotherapy dosimetry will lead to further trials in this field.
Trial registration: SEL-I-METRY is registered under ISRCTN17468602, 02/12/2015.
Keywords: Iodine refractory differentiated thyroid cancer, MEK inhibitor, Selumetinib, Radioiodoine therapy, Phase II,
Dosimetry
Background
Thyroid cancer is the most common endocrine malig-
nancy, but remains relatively rare despite incidence
doubling since the 1990s. In 2014, 3400 people in the
United Kingdom (UK) were diagnosed with thyroid can-
cer and in 2014 approximately 370 patients died from
the disease [1].
Current treatment
A combination of surgery, radioactive iodine (RAI) ther-
apy and long-term thyroid stimulating hormone (TSH)
suppression cures many patients with differentiated thy-
roid cancer, namely papillary and follicular cancers.
However around 10% of patients develop advanced dis-
ease which will eventually become resistant to therapy.
Prognosis for these patients is poor with a 10-year over-
all survival rate of 10% compared with 56% in patients
with RAI avid metastases [2].
Treatment for radioiodine refractory disease
Attempts have been made in the past to restore RAI
avidity with lithium carbonate [3] and retinoic acid [4],
but results have been disappointing and have failed to
show clear clinical benefit.
More recently a number of multi-targeted kinase inhibi-
tors have been tested; two phase III trials have shown sig-
nificant improvements in progression free survival (PFS)
with Sorafenib and Lenvatinib when compared with pla-
cebo [5, 6]. While these improvements are certainly to be
welcomed, both agents cause toxicities, including fatigue,
diarrhoea, hand-foot syndrome, weight loss and hyperten-
sion. Since they are taken continuously to disease progres-
sion this can have a significant impact on patients’ quality
of life.
MEK and radioiodine refractory disease
Mutations of RET, RAS or BRAF are present in approxi-
mately 70% of papillary thyroid cancers [7]. These onco-
genes are part of the mitogen-activated protein kinase
(MAPKinase) signalling pathway. Preclinical data suggest
that activation of this pathway is critical to tumour initi-
ation and transformation, and also results in reduced ex-
pression of genes involved in iodide metabolism, in
particular the sodium iodide symporter (NIS) which is
responsible for the uptake of iodine by thyroid cells. For
example, papillary thyroid cancers with BRAF mutations
are associated with reduced expression of key genes in-
volved in iodine metabolism, including NIS [8].
In vitro work with rat thyroid PCCL3 cells with in-
duced BRAF mutations has shown that treating the cells
with a MEK inhibitor restores expression of TSH recep-
tors, NIS and thyroglobulin, indicating that the effects of
BRAF mutation to reduce NIS expression are potentially
reversible [9].
Selumetinib
Selumetinib is an oral, potent and highly selective, allo-
steric MEK1/2 inhibitor. MEK1/2 are critical components
of the MAPKinase pathway. This pathway is frequently
dysregulated due to activating mutations in various onco-
genes, including RAS or RAF. Inhibition of MEK, which
lies downstream of these targets, blocks inappropriate sig-
nal transduction offering a promising therapeutic strategy.
Selumetinib is not currently approved for use in any
clinical indications in humans, but phase I and II trials
have been conducted in pancreatic cancer [10], melanoma
[11–16], non-small cell lung cancer [17–19] and differen-
tiated thyroid cancer [20–22] and it has recently been des-
ignated orphan drug status for treatment of differentiated
thyroid cancer in the United States. The drug has been
found to have an acceptable side effect profile; most
frequently reported side effects include diarrhoea,
nausea and vomiting, dyspnoea, blurred vision, tired-
ness and acneiform rash.
A previously reported pilot study [21] tested the use of
Selumetinib 75mg twice daily for four weeks in patients
with radioiodine refractory differentiated thyroid cancer.
All participants who started therapy were able to complete
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the full prescribed course of Selumetinib without dose re-
ductions or delays. No toxic effects of Grade 3 or above
were noted. Of 20 participants evaluated, Selumetinib in-
creased radioiodine uptake in 12 (60%). Eight of these 12
achieved sufficient increased uptake for further radioio-
dine therapy to be viable (67%). Of the eight participants
treated with radioiodine, five (63%) had partial responses
and three (38%) had stable disease. All participants had
decreases in serum thyroglobulin level.
Lesional dosimetry
Standard practice in the UK, endorsed by recently pub-
lished guidelines [23] is to prescribe an empirical activ-
ity, typically 3.7–7.4GBq iodine-131 (I-131) to patients
with metastatic disease. It is well recognised that this
leads to a wide range of absorbed dose delivered to
tumour targets and organs at risk, and therefore very
likely to lead to widely divergent outcomes. This is in
stark contrast to modern external-beam radiotherapy
practice where absorbed dose delivered to target vol-
umes and to nearby organs at risk is prescribed and can
be accurately measured. There have been calls to address
this issue [24]. There is evidence that the absorbed dose
delivered to thyroid remnants correlates with response
for patients undergoing radioiodine ablation [25] and
this study will investigate a similar relationship for pa-
tients with locally advanced or metastatic disease.
The previously described pilot study [21] used pre-
treatment iodine-124 (I-124) positron emission tomog-
raphy (PET) to estimate absorbed dose to individual
lesions. A minimum lesion absorbed dose of 20Gy was
chosen as a cut off for proceeding with further I-131
therapy. The choice of cut off used in this pilot does not
appear to have been made on the basis of any published
data. Additionally the absorbed doses were not verified
after treatment, unlike in this study.
SEL-I-METRY trial
The SEL-I-METRY trial has been designed to demon-
strate the broader clinical impact of the use of Selumeti-
nib therapy to re-sensitise radioiodine refractory thyroid
cancer patients to treatment with radioiodine. The trial
will address the dosimetry of I-131 therapy to investigate
the relationship between the absorbed dose delivered
and the clinical benefit from therapy. In addition the
extent to which the therapeutic activity of I-131 can be
individualised from the absorbed doses predicted in a
pre-therapy tracer study will be analysed using dosimet-
ric calculations. It will also explore possible biomarkers
for response to this strategy, including measurement of
post I-131 protein bound iodine (PBI) and molecular
markers both in tumour tissue and circulating cell-free
DNA.
Methods
Design
SEL-I-METRY is a UK, single arm, multi-centre, two-
stage phase II proof of concept trial investigating the use
of Selumetinib to resensitise iodine refractory patients
with differentiated thyroid cancer. To ensure at least 38
participants are treated with I-131, approximately 60 par-
ticipants will be recruited from eight NHS Hospitals. Par-
ticipants will receive 75mg of Selumetinib orally twice
daily for four weeks (dose may be reduced due to adverse
events) and will then be assessed for evidence of an in-
crease in radioiodine uptake via iodine-123 (I-123) single
photon emission computed tomography/computed tom-
ography (SPECT/CT); those showing sufficient uptake will
then receive I-131 therapy (further details on patient
imaging and dosimetry can be found in Additional file 1).
A previous pilot study [21] used I-124 sodium iodide
(NaI) although there is currently no commercially avail-
able source of this isotope in the UK. This trial therefore
elected to use I-123 as an alternative to determine changes
in radioiodine uptake following Selumetinib therapy, and
to predict likely lesional absorbed dose in participants pro-
ceeding to I-131 therapy. The use of I-123 as opposed to
I-124 is not thought to pose any significant risk to the
current trial; whilst theoretically there may be advantages
to using I-124, there are no known clinical comparator
studies between the two techniques and a pragmatic deci-
sion to use I-123 was deemed reasonable by the trial team.
An early stopping rule is incorporated in the case where
none of the first 10 patients treated with Selumetinib show
sufficient iodine uptake to progress to I-131 therapy;
should this happen the trial may be discontinued. The
study protocol and this manuscript have been written in
accordance with Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines [26]
(checklist included as an Additional file 2).
Ethical approval
The trial has received ethics approval from the NHS
National Research Ethics Service (NRES) East Midlands-
Leicester South (15/EM/0455).
Primary objective
This trial aims to assess the efficacy of Selumetinib
followed by I-131 therapy in iodine refractory patients
with differentiated thyroid cancer demonstrating increased
iodine uptake following initial treatment with Selumetinib.
The primary objective is to assess whether the treatment
schedule leads to increased PFS compared to historical
control data. PFS has been chosen as the primary end-
point assessing efficacy to allow for proof of concept in
this Phase II trial to be obtained in a quick and robust
manner and as it is clinically relevant to patients.
Brown et al. BMC Cancer          (2019) 19:582 Page 3 of 10
Secondary objectives
 Assess the safety and toxicity of Selumetinib;
 Assess efficacy based on response and overall
survival of Selumetinib followed by I-131 therapy;
 Determine the rate of iodine uptake in metastatic
lesions in iodine refractory patients with
differentiated thyroid cancer treated with
Selumetinib.
Exploratory objectives
 Investigate the role of lesional dosimetry using I-123
SPECT/CT to predict response to I-131 therapy;
 Assess correlation between PBI with absorbed doses
delivered and treatment outcome in patients who
receive I-131;
 Summarise BRAF, NRAS and TERT gene mutational
status, and additional mutational analysis of relevant
genes, from tissue and circulating cell-free DNA;
 Assess patient reported quality of life.
Sample size
Based on previous data, median progression free survival
is estimated to be approximately six months, correspond-
ing to 25% of patients alive and progression free at 12
months [5]; a clinically important increase suggesting fur-
ther investigation of Selumetinib (assuming exponential
survival) is deemed to be an increase to 44% (hazard ra-
tio = 0.6). Using a 1-sided 10% significance level, and with
80% power, 38 patients with sufficient radioiodine uptake
following Selumetinib therapy are required (allowing for
10% drop out), based on a Case and Morgan two-stage
design [27]. Assuming sufficient increase in iodine uptake
to warrant I-131 therapy in 60% of patients [21], approxi-
mately 60 patients will be recruited in total.
A formal interim analysis will be performed after 21 par-
ticipants with sufficient iodine uptake following Selumeti-
nib treatment have been recruited and after a minimum of
12months recruitment. If there is evidence to suggest that
12month progression free survival is no better than 25%
based upon the Nelson-Aalen estimator then the trial may
be terminated early for lack of activity.
If none of the first 10 participants treated with Selumeti-
nib has sufficient increase in iodine uptake to progress to
I-131 therapy, then the trial may be discontinued. This
corresponds to excluding an uptake rate of at least 26%
with 95% confidence.
Eligibility criteria
Inclusion and exclusion criteria can be found in Table 1.
Patients with Gilbert’s syndrome (persistent or recurrent
hyperbilirubinemia that is predominantly unconjugated
in the absence of evidence of haemolysis or hepatic
pathology) will be eligible. Eligibility waivers will not be
granted in this trial.
Consent, screening and registration
Written informed consent will be obtained prior to the
commencement of all trial assessments, tests and proce-
dures by authorised members of the trial team. Screen-
ing investigations will be conducted to confirm eligibility
following consent and prior to registration. These in-
vestigations will include: CT neck, chest, abdomen and
pelvis (without iodinated contrast); echocardiogram/mul-
tiple gated acquisition (MUGA); single 12-lead electrocar-
diogram (ECG); vital signs; ophthalmology examinations
(best corrected visual acuity; intraocular pressure and slit
lamp fundoscopy); full blood count (FBC); urea and elec-
trolytes (U&Es); liver function tests (LFTs) and thyroid
function tests (TFTs); serum pregnancy test for premeno-
pausal women. Eligible patients will then be registered to
the trial centrally via the University of Leeds automated
24 h system. Whenever possible, a biopsy of an identified
iodine refractory lesion will be obtained following registra-
tion; archival tissue from initial thyroidectomy will also be
requested.
Treatment and assessment schedules
Quality of life will be assessed within 28 days of registra-
tion for all participants, and tissue samples will be col-
lected within the same timeframe where applicable.
Participants will be asked to observe a low iodine diet
from two weeks prior to receiving a baseline I-123
SPECT/CT scan which must be completed within 28
days of registration; 0.9 mg recombinant human TSH
(rhTSH) will be given via intramuscular administration
two days and one day prior to administration of I-123.
Prior to day one of treatment participants will have fur-
ther assessments including repeat blood tests.
Participants will then be treated with 75 mg of oral
Selumetinib twice daily for four weeks; doses will be
taken approximately 12 h apart. Repeat assessments in-
cluding haematology and biochemistry will be conducted
on day 14 and day 28; where applicable blood samples
for cell-free DNA assessment will also be collected. An
I-123 SPECT/CT scan at the end of treatment, day 28 (±
1 day), will be reviewed centrally. The increase in uptake
will be deemed significant if there is presence of any clin-
ically relevant, targeted uptake in a lesion in which there
was previously no uptake or there is an increase of 30% or
more in uptake in a lesion with evidence of some uptake
on the baseline scan. Participants will be asked to recom-
mence the low iodine diet two weeks prior to the post
treatment scan and will again be administered 0.9mg
rhTSH two days and one day prior to the scan. Partici-
pants will continue to observe the low iodine diet and take
Selumetinib whilst the post treatment scan is undergoing
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Table 1 Eligibility criteria
Inclusion Criteria
- Diagnosed with locally advanced or metastatic differentiated thyroid
cancer (papillary, follicular, Hürthle cell, or poorly differentiated
carcinoma) with at least one measurable lesion as measured by
computed tomography (CT) or magnetic resonance imaging (MRI)
- Participants must have iodine refractory disease defined by
one or more of the following:
• One or more measurable lesions that do not demonstrate
iodine uptake on a previous radioiodine scan (diagnostic
uptake or post therapy)
OR
• One or more measurable lesions that have progressed by
RECIST 1.1 criteria within 12 months of I-131 therapy, despite
demonstrable radioiodine avidity at the time of that treatment
- Participants must have radiological progression by RECIST 1.1
criteria within the prior 12 months
- Measurable disease by RECIST 1.1 criteria. Baseline scan must
be completed within 4 weeks prior to the start of treatment.
- ECOG Performance Status ≤1 and able to tolerate radioiodine
therapy
- Life expectancy of at least 12 weeks
- Required laboratory values within 14 days of day 1 of treatment:
• Adequate thyroid-stimulating hormone (TSH) suppression
< 0.5 mU/L
• Creatinine clearance > 50 ml/min
• Absolute Neutrophil Count ≥1.5 × 109/L (1500 per mm3)
• Platelets ≥100 × 109/L (100,000 per mm3)
• Haemoglobin > 9.0 g/dL
• Serum bilirubin ≤1.5 x upper limit of normal (ULN)
• Patients with no liver metastasis must have AST or
ALT ≤2.5 x ULN
• Patients with liver metastasis must have AST or ALT ≤5 x ULN.
If patients have AST or ALT > 3.5 x ULN and≤ 5 x ULN they must
have an ALP ≤ 6 x ULN
- Able to give informed consent and willing to follow trial protocol.
- Aged over 18 years or over
- Female participants of child-bearing potential must have a negative
pregnancy test within 24 h prior to starting therapy and agree to use
dual methods of contraception for the duration of the trial and 6
months after completing treatment. Male participants must agree to
use a barrier method of contraception for the duration of the trial and
4 months after completing treatment, if sexually active with a female
of child-bearing potential.
- Able to swallow Selumetinib/I-131 capsules whole
Exclusion criteria
- Foci of anaplastic thyroid cancer
- Able to receive curative surgery or radiation therapy
- Major surgery (with the exception of surgical placement for vascular
access), open biopsy, or significant traumatic injury ≤30 days prior
to registration
- Previous or concurrent cancer distinct in primary site or histology from
thyroid cancer within previous 5 years, except for cervical cancer in
situ, treated basal cell carcinoma, or squamous cell carcinoma of the
skin or superficial bladder tumour
- Have received or are receiving an IMP or other systemic anticancer
treatment within 4 weeks prior to the first dose of study treatment (6
weeks for nitrosoureas, mitomycin, and suramin), or within a period
during which the IMP or anticancer treatment has not been cleared
from the body (e.g. a period of 5 ‘half-lives’), whichever is the most
appropriate and as judged by the investigator
- Any unresolved toxicity ≥CTCAE Grade 2 from previous anti-cancer
therapy, except for alopecia
Table 1 Eligibility criteria (Continued)
- Prior exposure to Tyrosine Kinase, MEK, RAS or RAF inhibitors
- Known or suspected allergy to Selumetinib or hypersensitivity to
Selumetinib or any excipient agents or history of allergic reactions
attributed to compounds of similar chemical or biologic composition
to Selumetinib
- Have known or suspected brain metastases or spinal cord
compression, unless the condition has been asymptomatic, has been
treated with surgery and / or radiation, and has been stable without
requiring corticosteroids nor anti-convulsant medications for at least 4
weeks prior to the first dose of study medication.
- Requiring medication with high iodine content (e.g. amiodarone)
- Participants who have had a Iodine contrast enhanced CT scan in
previous 2 months
- Ophthalmological conditions as follows:
• Intra-ocular pressure > 21 mmHg, or uncontrolled glaucoma
(irrespective of intra-ocular pressure)
• Current or past history of retinal pigment epithelial detachment
(REPD)/central serous retinopathy or retinal vein occlusion
- Any of the following cardiac conditions
• Uncontrolled hypertension (BP ≥150/95 mmHg despite
medical therapy)
• Acute coronary syndrome within 6 months prior to starting
treatment
• Uncontrolled angina (Canadian Cardiovascular Society grade
II-IV despite medical therapy)
• Symptomatic heart failure (NYHA grade II-IV), prior or current
cardiomyopathy, or severe valvular heart disease
• Prior or current cardiomyopathy including but not limited to
the following:
• Known hypertrophic cardiomyopathy
• Known arrhythmogenic right ventricular cardiomyopathy
• Severe valvular heart disease
• Left ventricular ejection fraction < 55% measured by
echocardiography
• Atrial fibrillation with a ventricular rate > 100 bpm on ECG at rest
• QTcF > 450 ms or other factors that increase the risk of QT
prolongation
- Participants known to be infected with human immunodeficiency virus
(HIV) or hepatitis B (HBV) or C (HCV) virus
- Any evidence of severe or uncontrolled systemic disease
(e.g. unstable or uncompensated respiratory, cardiac, hepatic,
or renal disease), active infection, active bleeding (including
hepatitis B, hepatitis C, HIV), diatheses or renal transplant.
- Pregnant or breastfeeding females
- Male or female patients of reproductive potential and, as judged by
the investigator, are not employing an effective method of birth control
- Have evidence of any other significant clinical disorder or laboratory
finding that, as judged by the investigator, makes it undesirable for the
patient to participate in the study.
- Hypersensitivity to bovine or human thyroid stimulating hormone or
to any of the following excipients; mannitol, sodium phosphate
monobasic, monohydrate, sodium phosphate dibasic, heptahydrate or
sodium chloride.
- Hypersensitivity to I-123 or I-131 or to any of the following excipients;
acetic acid, sodium hydroxide, sodium thiosulphate, sodium
bicarbonate, sodium chloride, disodium phosphate anhydrous or silica
- Patients with dysphagia, oesophageal stricture, active gastritis, gastric
erosions and peptic ulcer.
- Have refractory nausea and vomiting, chronic gastrointestinal diseases
(e.g., inflammatory bowel disease), suspected reduced gastrointestinal
motility or significant bowel resection that would adversely affect the
absorption/bioavailability of orally administered study medication.
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review (for a maximum of 18 days). A further two to three
SPECT/CT scans will also be acquired and used to predict
the radiation dose that may be achieved with radioiodine
treatment.
Participants not deemed to have sufficient increase in
iodine uptake will cease treatment with Selumetinib, can
return to a usual diet and will continue to be followed
up for safety purposes until 30 days after completion of
Selumetinib treatment. These individuals will receive no
further trial treatment.
Participants with sufficient increase of iodine uptake
will go on to receive treatment with I-131 and will con-
tinue to take Selumetinib until two days after adminis-
tration of I-131 (if applicable) when the low iodine diet
can be discontinued. rhTSH 0.9 mg will be administered
two days and one day prior to I-131 therapy. An activity
of 5.5 GBq (±10%) I-131 sodium iodide will be adminis-
tered orally. In the absence of any strong evidence of
benefit from a dosimetric approach, it is felt reasonable
to stick to empirical activities as per current standard
UK practice. However, following I-131 therapy, dosim-
etry calculations will be made from three to four
SPECT/CT scans. A standardised calibration protocol
will be used by sites to optimise and standardise SPECT/
CT image data across participants. Therefore an essen-
tial element of the this trial is the need to set up, for the
first time, a network of UK centres able to perform
quantitative I-123 and high activity I-131 imaging.
For participants consenting to blood sample collection
for PBI analysis, samples will be collected 24 and 144 h
post I-131 therapy.
Upon completion of I-131 therapy, participants will
be followed up quarterly for the first 12 months and
then 6 monthly for the duration of the trial (i.e.
until the last patient recruited reaches 12 months
follow up) or until evidence of disease progression is
confirmed by CT scan. Follow-up assessments will
include measurement of thyroglobulin and antithyro-
globulin antibodies; thyroid function test; CT neck,
thorax, abdomen and pelvis. Quality of life assess-
ments will be repeated at each follow up for the first
12 months, and where applicable blood sample col-
lection for cell-free DNA assessment will occur at
three months and six months.
For all participants, TSH suppression to less than 0.1
units should be maintained throughout treatment and
follow-up. Also, for all participants (including those not
receiving I-131 therapy), assessments at 30 days post end
of Selumetinib treatment will include vital signs, 12-lead
ECG, haematology, echocardiogram and repeat quality
of life measures.
The participant pathway can be seen schematically
in Fig. 1, and Table 2 (SPIRIT diagram) details the
assessment schedule.
Outcomes
Primary endpoint
The primary endpoint of the trial is PFS at 12 months,
reported as the percentage of participants alive and
progression-free at 12 months. PFS is calculated from
date of registration to first documented evidence of dis-
ease progression or death. Participants who have not
progressed at the time of analysis will be censored at the
last date alive and progression-free.
Secondary endpoints
 Safety: Serious adverse events (SAEs) from
registration until 30 days post cessation of trial
therapy (Selumetinib or I-131 therapy); suspected
unexpected serious adverse reactions (SUSARs) and
serious adverse reaction (SARs) recorded for all
from start of protocol treatment for the lifetime of
the trial;
 Toxicity: Adverse reactions (ARs) as graded by
common terminology criteria for adverse events
(CTCAE) v4.0;
 Overall survival (OS): calculated from date of
registration to date of death; censoring will occur at
last known date alive for those alive at time of analysis;
 Sufficient iodine uptake: reviewed centrally; sufficient
uptake is defined as presence of any clinically relevant
uptake in a lesion in which there was previously no
uptake or an increase of 30% or more in uptake in a
lesion with evidence of some uptake on the baseline
scan;
 Radiological response: assessed via CT scans and
based on response evaluation criteria in solid
tumours (RECIST) v1.1.
Exploratory endpoints
 Lesional and whole body dosimetry: As measured from
a minimum of three and maximum of four SPECT/CT
scans over six days following Selumetinib and I-131;
 BRAF, NRAS and TERT gene mutational status and
additional relevant genes: from circulating cell-free
DNA, iodine refractory tissue samples and historic
tissue samples where available;
 PBI levels from blood samples;
 Quality of life: assessed using QLQ-C30 plus head and
neck cancer supplementary questions (H&N35), and
EQ-5D™;
 Change in serum thyroglobulin levels: assessed via
percentage change from baseline at each time point.
Analysis
Statistical analysis for final and interim analyses are fully
detailed in separate analysis plans. The full analysis set
will include all registered participants receiving at least one
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dose of Selumetinib and will be equivalent to the safety
analysis set. The iodine uptake (IU) cohort will include par-
ticipants from the full analysis set who were deemed to
have sufficient I-123 uptake following treatment with Selu-
metinib. All other participants in the full analysis set will be
the non-IU cohort. All efficacy endpoint analyses will be
conducted on the IU cohort only, unless otherwise specified
in the analysis plan. Safety analyses will be conducted on
the safety analysis set with data summarised for each study
cohort and overall during initial therapy.
Primary endpoint analysis
The proportion of participants alive and progression free
at 12 months will be presented with corresponding
confidence intervals (CI). The primary analysis will test
the hypothesis that PFS in the IU cohort is less than or
equal to 25%, against an alternative of 44% based on the
Nelson-Aalen estimate of the cumulative hazard func-
tion at 12 months, following the methodology of Case
and Morgan [27].
Secondary endpoint analyses
SAEs, SARs and SUSARs will be reported overall and by
treatment period (Selumetinib, I-131) for all participants
and for the IU and non-IU cohorts.
The number and proportion of participants experien-
cing each grade of toxicity will be summarised in the
same analysis sets.
Fig. 1 Participant pathway
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OS will be summarised using Kaplan-Meier curves;
OS at 12 months and median OS will both be presented
alongside CIs.
The proportion of participants with sufficient iodine
uptake to progress to I-131 will be presented with
corresponding 95% CI. This will also be presented ex-
cluding individuals who did not receive Selumetinib
for seven days prior to the scan.
The proportion of participants in the IU cohort achieving
at least a partial response will be presented with 95% CIs.
The proportion of participants in each best response cat-
egory (complete response, partial response, stable disease,
and progressive disease) will also be presented.
Exploratory endpoint analyses
The absorbed dose to each lesion, whole body and blood
measurements will be presented descriptively alongside
measures of uncertainty. Regression modelling will be
used to investigate association between these doses and
outcome as appropriate. Analogous analyses will explore
association between lesional absorbed dose, radiological
response and overall survival, as will analyses consider-
ing whole body and blood absorbed doses and grades of
toxicity.
Gene mutational status will be summarised for all
available samples. PFS and response will be summarised
by gene mutational status.
Table 2 Minimum schedule of assessments (SPIRIT diagram)
Baseline Treatment End of Treatment Follow Up
Within 14 days
prior to registration
Within 28 days
of registration
Selumetinib I-131
Therapy
30 days post end
of Selumetinib
treatment
3 monthly for first
12 months then 6
monthly for duration
of trialb
Day 1 Day 14 Day 28
Informed consent X
Patient details (initials, date
of birth, sex)
X
Medical History X
Physical Examination/Vital signs X X X X X X
Ophthalmologic assessment X
12-Lead ECG X X X
Laboratory tests X X X X X X
Pregnancy test X X X X Xc
Echocardiography /MUGA X X
Dispensing of Selumetinib X
Tissue collection X
CT neck, thorax, abdomen
and pelvis
Xa X
I-123 SPECT/CT X X
SPECT/CT for Lesion Dosimetry
post I-131 therapy
X
Adverse Events X X X X X X Xd
Concomitant Medications X X X X X
Quality of life (QLQ-C30,
QLQ-H&N35 and EQ-5D™)
X X Xe
Protein bound iodine blood
sample collection
Xf
Cell-free DNA blood sample
collection
X X X X Xg
aif CT scans have not been performed within 28 days of starting treatment, an additional CT neck, chest, abdomen, and pelvis must be performed to enable
assessment of response and progression-free survival as per RECIST criteria
bParticipants who do not proceed to radioiodine therapy will be followed up for safety purposes until 30 days after completion of Selumetinib treatment only
cPregnancy test to be done at the first and second 3 monthly follow up visits (3 month and 6month follow-up)
dAdverse reactions only at follow up visits
eQuality of life is assessed at baseline, end of treatment and 3 monthly for the first 12 months of follow-up
fCollected 24 and 144 h following I-131 dosing
g3 and 6months only
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PBI measurements will be summarised for all partici-
pants receiving I-131 with samples available. The rela-
tionship between absorbed dose delivered and treatment
outcome will be investigated.
Quality of life will be summarised with 95% CIs adjust-
ing for baseline mean scores. The QLQ-C30 and
H&N35 will be summarised for each domain. The pro-
portion of participants scoring each category for the five
EQ-5D™ domains will be presented.
Mean change in thyroglobulin from baseline at each time
point will be presented with corresponding standard error.
Mean change will also be presented by maximum RECIST
response. A waterfall plot of maximum change per partici-
pant will be presented.
Trial and data monitoring
A Trial Steering Committee will be convened to period-
ically review safety data; an independent Data Monitor-
ing and Ethics Committee (DMEC) will review safety
data to determine patterns and trends of events which
would not be apparent on an individual case basis. Fol-
lowing the interim analysis, the DMEC may request that
the trial be terminated for lack of activity if there is evi-
dence to suggest that 12 month PFS is no better than
25% based on the Nelson-Aalen estimator.
Discussion
The SEL-I-METRY trial will investigate a potential treat-
ment to resensitise radioiodine refractory patients with
differentiated thyroid cancer. Current treatment options
for this group of patients, the multi-targeted kinase in-
hibitors Sorafenib and Lenvatinib, need to be given con-
tinuously and are associated with significant toxicity and
hence may be detrimental to quality of life.
Patients who have radioiodine avid disease have better
survival outcomes and thus resensitising refractory pa-
tients could lead to improvements in progression-free
survival without the need for continuous treatment and
the associated toxicity. There are already considerable
data regarding the tolerability of the Selumetinib regi-
men, and a pilot trial found an indication of an increase
in iodine uptake. Both toxicity and efficacy will be
assessed in this larger Phase II multicentre trial.
If the SEL-I-METRY trial demonstrates that Selumeti-
nib followed by further I-131 NaI is a useful treatment
strategy for this group of patients, a randomised trial
comparing this approach with other treatments, such as
the multi-kinase inhibitors, could be considered to help
define the optimal treatment for these patients.
In addition, an essential element of this trial is the need
to set up, for the first time, a network of UK centres able
to perform quantitative high activity I-131 imaging which
is essential for dosimetric calculations. This information
will be collected to investigate prediction of response to
I-131, presenting an unprecedented opportunity to inves-
tigate the role of lesional dosimetry in molecular radio-
therapy, leading to greater personalisation of therapy, both
with I-131 and with other isotope therapies.
Trial status
At the time of submission, SEL-I-METRY is open to
recruitment.
Additional file
Additional file 1: Patient Imaging and Dosimetry Protocol. (DOC 19 kb)
Additional file 2: Recommended items to address in a clinical trial
protocol and related documents*. (DOC 122 kb)
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